The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Medical Aesthetics Machine Market The growing popularity of non-invasive cosmetic procedures is a major driver of the Global Medical Aesthe ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing ...